Type of Assessment:
Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells
Cancers 2021 February 6 [Link] Joman Javadi, Ghazal Heidari-Hamedani, Angelika Schmalzl, Tünde Szatmári, Muzaffer Metintas, Pontus Aspenström, Anders Hjerpe, Katalin Dobra Abstract Malignant mesothelioma (MM) is an aggressive tumor of the serosal cavities. Angiogenesis is important for mesothelioma progression, but so far, anti-angiogenic agents have not improved patient survival. Our hypothesis is that better understanding…
Read MoreSerum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial
Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…
Read MorePotential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma
Oncology Letters 2021 February [Link] Vincenzo Fontana, Maria Pia Pistillo, Antonella Vigani, Pier Aldo Canessa, Giovanni Berisso, Ugo Giannoni, Paola Ferro, Maria Cristiana Franceschini, Roberta Carosio, Marika Tonarelli, Paolo Dessanti, Silvio Roncella Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor survival rates. Therefore, it is essential to have effective biological markers predicting…
Read MoreA novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20 : a case report and literature review
The Oncologist 2021 February 8 [Link] Chiho Miyagawa, Hisamitsu Takaya, Kazuko Sakai, Kazuto Nishio, Maho Konishi, Sachiko Minamiguchi, Toshihide Shimada, Noriomi Matsumura Abstract Recently, several malignant peritoneal mesothelioma (MPMs) that occur in young women without asbestos exposure and with fusion genes such as anaplastic lymphoma kinase (ALK) and Ewing sarcoma breakpoint region 1 (EWSR1) have…
Read MoreAlterations in BAP1 are Associated with Cisplatin Resistance Through Inhibition of Apoptosis in Malignant Pleural Mesothelioma (MPM)
Clinical Cancer Research 2021 February 5 [Link] Kathrin Oehl, Bart Vrugt, Ulrich Wagner, Michaela B Kirschner, Mayura Meerang, Walter Weder, Emanuela Felley-Bosco, Bernd Wollscheid, Katrin Bankov, Melanie C Demes, Isabelle Opitz, Peter J Wild Abstract Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of…
Read MoreMetformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells
Frontiers in Cell and Development Biology 2021 January 18 [Link] Marika Rossini, Fernanda Martini, Elena Torreggiani, Francesca Fortini, Giorgio Aquila, Francesco Vieceli Dalla Sega, Simone Patergnani, Paolo Pinton, Pio Maniscalco, Giorgio Cavallesco, Paola Rizzo, Mauro Tognon Abstract Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related cancer arising from the mesothelial cells lining the pleural cavity.…
Read MoreMalignant pleural mesothelioma in a patient with pneumothorax: A cumbersome subtype both clinically and pathologically
Thoracic Cancer 2021 February 2 [Link] Takafumi Fukui, Takako Okubo, Naoki Tanimoto, Hiromichi Okuma, Yoshitaka Shiina, Mizuki Kohama, Jun Yamada, Yasuhiro Funada, Yoshihiro Ikura Abstract Here, we report a case of malignant pleural mesothelioma (MPM) that was very difficult to diagnose. A 62-year-old woman with a surgical history of recurrent bilateral pneumothorax was admitted to…
Read MoreSwitch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
The Lancet Respiratory Medicine 2021 January 27 [Link] Cornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, Paul Baas, Bonne Biesma, Robin Cornelissen, Nico van Walree, Robbert C van Heemst, Magdolen Youssef-El Soud, Harry J M Groen, Agnes J Staal-van den Brekel, Wieneke A Buikhuisen, Gerben P Bootsma, Floris Dammeijer, Harm van Tinteren,…
Read MoreRucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
The Lancet Respiratory Medicine 2021 January 27 [Link] Dean A Fennell, Amy King, Seid Mohammed, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Adrian Nicholson, Cathy Richards, Peter Wells-Jordan, Gavin James Murphy, Anne Thomas Abstract Background: Malignant mesothelioma remains an incurable cancer, with no effective treatments in the…
Read MoreUnusual radiologic presentations of malignant peritoneal mesothelioma
World Journal of Radiology 2020 December 28 [Link] Paul Hendrick Sugarbaker, James S Jelinek Abstract Background: Malignant peritoneal mesothelioma is an unusual disease process characterized radiologically by ascites and infiltration of the peritoneum by multiple small tumor nodules. Both parietal and visceral peritoneum are involved by the multiple malignant tumor nodules. Computed tomography (CT) has…
Read More